In vitro incubation of a spliceosome-targeted drug (TG003) showed that CP-CML CD34+ cells are spliceosome dependent; moreover, with the combination of TKI, the two drugs showing an additive effect while sparing healthy donors cells. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.